Novo and Sofinnova Partners have co-led a series B round for Rgenix, which is preparing to enter two immunotherapies into clinical trials this autumn.
US-based immunotherapy developer Rgenix received $33m yesterday in a series B round co-led by pharmaceutical firm Novo and venture capital firm Sofinnova Partners.
The round also featured real estate investment trust Alexandria Real Estate Equities’ Alexandria Venture Investments subsidiary, Partnership Fund for New York City and private equity firm Conegliano Ventures.
Rgenix is working on cancer therapies that are able to reverse drug resistance, and will use the series B capital to launch clinical trials for its two lead candidates…
